Phase 3 N=147 Corneal Collagen Cross-linking for Progressive Keratoconus
Progressive Keratoconus
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -1.7; 0.6 diopters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=17 Effects of Compression Stockings on Obstructive Sleep Apnea in Patients Under Hemodialysis
Renal Failure Chronic Requiring Dialysis · Obstructive Sleep Apnea
Primary: Change of Obstructive Apnea Severity Index Score From Baseline — 20.8; 16.7 events/hour
Phase 2 N=121 Modulation of Immune Activation by Aspirin
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 11/12 — 0.99; 1.03; 0.97 fold change — p=0.70
Phase 1 N=20 A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants
Healthy Volunteer
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Cobimetinib — 778; 864; 846 nanograms*hours/milliliter (ng*hr/mL)
Phase 4 N=111 Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler
Asthma
Primary: Percentage of Participants Making at Least One Critical Error After the First Assessment of Metered Dose Inhaler (MDI) Technique on Day 14 — 14 Percentage of Participants
Phase 2 N=35 Cabozantinib for Metastatic Triple Negative BrCa
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
Phase 2 N=103 Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Reporting a Dose Limiting Toxicity (DLT) — 1; 0; 1; 2 participants
N/A N=110 Analgesia in Laparoscopic Cholecystectomy
Pain, Postoperative · Chronic Postoperative Pain
Primary: VAS Score Changes ( Cough) During 24 h Postoperatively — 32; 31 mm
Phase 2 N=66 Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
PBC · Primary Biliary Cirrhosis
Primary: Change From Baseline in Pruritus Using Adult Itch Reported Outcome (ItchRO) Weekly Sum Score at Week 13/ Early Termination (ET) — 48.11; 52.10; 54.64; 49.46 units on a…
N/A N=72 Nitrous Oxide for Pain Management During In-office Transcervical Sterilization
Contraception · Inhalation of Nitrous Oxide
Primary: Change From Baseline in Pain Scale Measurement During and After the Procedure — 1.1; 2.5; 15.6; 15.4 units on a scale
N/A N=100 Comparative Study of Ropivacaine and Ropivacaine With Dexmeditomedine in TAP Blocks
Pregnancy
Primary: The Time After the TAP Block When Rescue Analgesia Was First Sought — 13.12; 18.21 Hours
Phase 4 N=489 Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
Rheumatoid Arthritis
Primary: Percentage of Participants Who Remained in Low Disease Activity (LDA) (Disease Activity Score in 28 Joints-erythrocyte Sedimentation Rate [DAS28-ESR] <3.2) at Week 52…
Phase 4 N=23 A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection
HIV Infections
Primary: Number of Participants With Serious Adverse Events (SAEs) — 6 participants
Phase 1 N=52 A Bioequivalence Study of TAK-536 Pediatric Formulation
Japanese Healthy Adult Males
Primary: AUC(0-48): Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose for TAK-536 in Dry Syrup Cohort — 7065.6; 7341.2 nanogram*hour per milliliter…
Phase 3 N=455 Osteopathic Health Outcomes in Chronic Low Back Pain (OSTEOPATHIC) Trial
Low Back Pain
Primary: Change in Visual Analogue Scale Score for Pain Over 12 Weeks (OMT vs Sham OMT) — 40; 20 participants — p=0.007